 | • レポートコード：MRC2-11QY01124 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肝性脳症治療薬のグローバル市場について調査・分析したレポートです。種類別（RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肝性脳症治療薬の競争状況、市場シェア ・世界の肝性脳症治療薬市場：種類別市場規模 2015年-2020年（RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他） ・世界の肝性脳症治療薬市場：種類別市場規模予測 2021年-2026年（RBX-2660、KLS-13019、GR-3027、SYNB-1020、その他） ・世界の肝性脳症治療薬市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の肝性脳症治療薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の肝性脳症治療薬市場分析：米国、カナダ ・ヨーロッパの肝性脳症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肝性脳症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肝性脳症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肝性脳症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Alfa Wassermann S.p.A、Cosmo Pharmaceuticals S.p.A、Horizon Pharma Plc、KannaLife Sciences, Inc.、Ocera Therapeutics, Inc.、Rebiotix Inc.、Spherium Biomed S.L.、Umecrine Cognition AB ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Hepatic Encephalopathy Drug Market
The global Hepatic Encephalopathy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hepatic Encephalopathy Drug Scope and Market Size
Hepatic Encephalopathy Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatic Encephalopathy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hepatic Encephalopathy Drug market is segmented into
RBX-2660
KLS-13019
GR-3027
SYNB-1020
Others
Segment by Application, the Hepatic Encephalopathy Drug market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Hepatic Encephalopathy Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hepatic Encephalopathy Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hepatic Encephalopathy Drug Market Share Analysis
Hepatic Encephalopathy Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hepatic Encephalopathy Drug business, the date to enter into the Hepatic Encephalopathy Drug market, Hepatic Encephalopathy Drug product introduction, recent developments, etc.
The major vendors covered:
Alfa Wassermann S.p.A
Cosmo Pharmaceuticals S.p.A
Horizon Pharma Plc
KannaLife Sciences, Inc.
Ocera Therapeutics, Inc.
Rebiotix Inc.
Spherium Biomed S.L.
Umecrine Cognition AB
1 Study Coverage
1.1 Hepatic Encephalopathy Drug Product Introduction
1.2 Market Segments
1.3 Key Hepatic Encephalopathy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type
1.4.2 RBX-2660
1.4.3 KLS-13019
1.4.4 GR-3027
1.4.5 SYNB-1020
1.4.6 Others
1.5 Market by Application
1.5.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hepatic Encephalopathy Drug Market Size, Estimates and Forecasts
2.1.1 Global Hepatic Encephalopathy Drug Revenue 2015-2026
2.1.2 Global Hepatic Encephalopathy Drug Sales 2015-2026
2.2 Global Hepatic Encephalopathy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hepatic Encephalopathy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hepatic Encephalopathy Drug Competitor Landscape by Players
3.1 Hepatic Encephalopathy Drug Sales by Manufacturers
3.1.1 Hepatic Encephalopathy Drug Sales by Manufacturers (2015-2020)
3.1.2 Hepatic Encephalopathy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Hepatic Encephalopathy Drug Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hepatic Encephalopathy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drug Revenue in 2019
3.2.5 Global Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hepatic Encephalopathy Drug Price by Manufacturers
3.4 Hepatic Encephalopathy Drug Manufacturing Base Distribution, Product Types
3.4.1 Hepatic Encephalopathy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatic Encephalopathy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Hepatic Encephalopathy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatic Encephalopathy Drug Market Size by Type (2015-2020)
4.1.1 Global Hepatic Encephalopathy Drug Sales by Type (2015-2020)
4.1.2 Global Hepatic Encephalopathy Drug Revenue by Type (2015-2020)
4.1.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hepatic Encephalopathy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Hepatic Encephalopathy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hepatic Encephalopathy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hepatic Encephalopathy Drug Market Size by Application (2015-2020)
5.1.1 Global Hepatic Encephalopathy Drug Sales by Application (2015-2020)
5.1.2 Global Hepatic Encephalopathy Drug Revenue by Application (2015-2020)
5.1.3 Hepatic Encephalopathy Drug Price by Application (2015-2020)
5.2 Hepatic Encephalopathy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Hepatic Encephalopathy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatic Encephalopathy Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hepatic Encephalopathy Drug by Country
6.1.1 North America Hepatic Encephalopathy Drug Sales by Country
6.1.2 North America Hepatic Encephalopathy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hepatic Encephalopathy Drug Market Facts & Figures by Type
6.3 North America Hepatic Encephalopathy Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Hepatic Encephalopathy Drug by Country
7.1.1 Europe Hepatic Encephalopathy Drug Sales by Country
7.1.2 Europe Hepatic Encephalopathy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Type
7.3 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hepatic Encephalopathy Drug by Region
8.1.1 Asia Pacific Hepatic Encephalopathy Drug Sales by Region
8.1.2 Asia Pacific Hepatic Encephalopathy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Type
8.3 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hepatic Encephalopathy Drug by Country
9.1.1 Latin America Hepatic Encephalopathy Drug Sales by Country
9.1.2 Latin America Hepatic Encephalopathy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Type
9.3 Central & South America Hepatic Encephalopathy Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hepatic Encephalopathy Drug by Country
10.1.1 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country
10.1.2 Middle East and Africa Hepatic Encephalopathy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments
11.2 Cosmo Pharmaceuticals S.p.A
11.2.1 Cosmo Pharmaceuticals S.p.A Corporation Information
11.2.2 Cosmo Pharmaceuticals S.p.A Description and Business Overview
11.2.3 Cosmo Pharmaceuticals S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Products Offered
11.2.5 Cosmo Pharmaceuticals S.p.A Related Developments
11.3 Horizon Pharma Plc
11.3.1 Horizon Pharma Plc Corporation Information
11.3.2 Horizon Pharma Plc Description and Business Overview
11.3.3 Horizon Pharma Plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Products Offered
11.3.5 Horizon Pharma Plc Related Developments
11.4 KannaLife Sciences, Inc.
11.4.1 KannaLife Sciences, Inc. Corporation Information
11.4.2 KannaLife Sciences, Inc. Description and Business Overview
11.4.3 KannaLife Sciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Products Offered
11.4.5 KannaLife Sciences, Inc. Related Developments
11.5 Ocera Therapeutics, Inc.
11.5.1 Ocera Therapeutics, Inc. Corporation Information
11.5.2 Ocera Therapeutics, Inc. Description and Business Overview
11.5.3 Ocera Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Products Offered
11.5.5 Ocera Therapeutics, Inc. Related Developments
11.6 Rebiotix Inc.
11.6.1 Rebiotix Inc. Corporation Information
11.6.2 Rebiotix Inc. Description and Business Overview
11.6.3 Rebiotix Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Rebiotix Inc. Hepatic Encephalopathy Drug Products Offered
11.6.5 Rebiotix Inc. Related Developments
11.7 Spherium Biomed S.L.
11.7.1 Spherium Biomed S.L. Corporation Information
11.7.2 Spherium Biomed S.L. Description and Business Overview
11.7.3 Spherium Biomed S.L. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Products Offered
11.7.5 Spherium Biomed S.L. Related Developments
11.8 Umecrine Cognition AB
11.8.1 Umecrine Cognition AB Corporation Information
11.8.2 Umecrine Cognition AB Description and Business Overview
11.8.3 Umecrine Cognition AB Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Products Offered
11.8.5 Umecrine Cognition AB Related Developments
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Corporation Information
11.1.2 Alfa Wassermann S.p.A Description and Business Overview
11.1.3 Alfa Wassermann S.p.A Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products Offered
11.1.5 Alfa Wassermann S.p.A Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hepatic Encephalopathy Drug Market Estimates and Projections by Region
12.1.1 Global Hepatic Encephalopathy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Hepatic Encephalopathy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.2.2 North America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hepatic Encephalopathy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hepatic Encephalopathy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hepatic Encephalopathy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hepatic Encephalopathy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hepatic Encephalopathy Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hepatic Encephalopathy Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatic Encephalopathy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hepatic Encephalopathy Drug Market Segments
Table 2. Ranking of Global Top Hepatic Encephalopathy Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of RBX-2660
Table 5. Major Manufacturers of KLS-13019
Table 6. Major Manufacturers of GR-3027
Table 7. Major Manufacturers of SYNB-1020
Table 8. Major Manufacturers of Others
Table 9. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Hepatic Encephalopathy Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Hepatic Encephalopathy Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Hepatic Encephalopathy Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Hepatic Encephalopathy Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Hepatic Encephalopathy Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Hepatic Encephalopathy Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Hepatic Encephalopathy Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Hepatic Encephalopathy Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drug as of 2019)
Table 18. Hepatic Encephalopathy Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Hepatic Encephalopathy Drug Price (2015-2020) (USD/Pcs)
Table 21. Hepatic Encephalopathy Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Hepatic Encephalopathy Drug Product Type
Table 23. Date of International Manufacturers Enter into Hepatic Encephalopathy Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Hepatic Encephalopathy Drug Sales Share by Type (2015-2020)
Table 27. Global Hepatic Encephalopathy Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Hepatic Encephalopathy Drug Revenue Share by Type (2015-2020)
Table 29. Hepatic Encephalopathy Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Hepatic Encephalopathy Drug Sales Share by Application (2015-2020)
Table 32. North America Hepatic Encephalopathy Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Hepatic Encephalopathy Drug Sales Market Share by Country (2015-2020)
Table 34. North America Hepatic Encephalopathy Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Hepatic Encephalopathy Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Table 38. North America Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Hepatic Encephalopathy Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Hepatic Encephalopathy Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Hepatic Encephalopathy Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Hepatic Encephalopathy Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Hepatic Encephalopathy Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Hepatic Encephalopathy Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Hepatic Encephalopathy Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Hepatic Encephalopathy Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Hepatic Encephalopathy Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Hepatic Encephalopathy Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Hepatic Encephalopathy Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Hepatic Encephalopathy Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hepatic Encephalopathy Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Hepatic Encephalopathy Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Hepatic Encephalopathy Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Hepatic Encephalopathy Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Table 72. Alfa Wassermann S.p.A Corporation Information
Table 73. Alfa Wassermann S.p.A Description and Major Businesses
Table 74. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Alfa Wassermann S.p.A Product
Table 76. Alfa Wassermann S.p.A Recent Development
Table 77. Cosmo Pharmaceuticals S.p.A Corporation Information
Table 78. Cosmo Pharmaceuticals S.p.A Description and Major Businesses
Table 79. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Cosmo Pharmaceuticals S.p.A Product
Table 81. Cosmo Pharmaceuticals S.p.A Recent Development
Table 82. Horizon Pharma Plc Corporation Information
Table 83. Horizon Pharma Plc Description and Major Businesses
Table 84. Horizon Pharma Plc Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Horizon Pharma Plc Product
Table 86. Horizon Pharma Plc Recent Development
Table 87. KannaLife Sciences, Inc. Corporation Information
Table 88. KannaLife Sciences, Inc. Description and Major Businesses
Table 89. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. KannaLife Sciences, Inc. Product
Table 91. KannaLife Sciences, Inc. Recent Development
Table 92. Ocera Therapeutics, Inc. Corporation Information
Table 93. Ocera Therapeutics, Inc. Description and Major Businesses
Table 94. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Ocera Therapeutics, Inc. Product
Table 96. Ocera Therapeutics, Inc. Recent Development
Table 97. Rebiotix Inc. Corporation Information
Table 98. Rebiotix Inc. Description and Major Businesses
Table 99. Rebiotix Inc. Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Rebiotix Inc. Product
Table 101. Rebiotix Inc. Recent Development
Table 102. Spherium Biomed S.L. Corporation Information
Table 103. Spherium Biomed S.L. Description and Major Businesses
Table 104. Spherium Biomed S.L. Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Spherium Biomed S.L. Product
Table 106. Spherium Biomed S.L. Recent Development
Table 107. Umecrine Cognition AB Corporation Information
Table 108. Umecrine Cognition AB Description and Major Businesses
Table 109. Umecrine Cognition AB Hepatic Encephalopathy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Umecrine Cognition AB Product
Table 111. Umecrine Cognition AB Recent Development
Table 112. Global Hepatic Encephalopathy Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 113. Global Hepatic Encephalopathy Drug Sales Market Share Forecast by Regions (2021-2026)
Table 114. Global Hepatic Encephalopathy Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 115. Global Hepatic Encephalopathy Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 116. North America: Hepatic Encephalopathy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 117. North America: Hepatic Encephalopathy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 118. Europe: Hepatic Encephalopathy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 119. Europe: Hepatic Encephalopathy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 120. Asia Pacific: Hepatic Encephalopathy Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 121. Asia Pacific: Hepatic Encephalopathy Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 122. Latin America: Hepatic Encephalopathy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 123. Latin America: Hepatic Encephalopathy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 124. Middle East and Africa: Hepatic Encephalopathy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 125. Middle East and Africa: Hepatic Encephalopathy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 126. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 127. Key Challenges
Table 128. Market Risks
Table 129. Main Points Interviewed from Key Hepatic Encephalopathy Drug Players
Table 130. Hepatic Encephalopathy Drug Customers List
Table 131. Hepatic Encephalopathy Drug Distributors List
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drug Product Picture
Figure 2. Global Hepatic Encephalopathy Drug Sales Market Share by Type in 2020 & 2026
Figure 3. RBX-2660 Product Picture
Figure 4. KLS-13019 Product Picture
Figure 5. GR-3027 Product Picture
Figure 6. SYNB-1020 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Hepatic Encephalopathy Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Hepatic Encephalopathy Drug Report Years Considered
Figure 13. Global Hepatic Encephalopathy Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Hepatic Encephalopathy Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Hepatic Encephalopathy Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Hepatic Encephalopathy Drug Sales Market Share by Region in 2019
Figure 18. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Hepatic Encephalopathy Drug Revenue Market Share by Region in 2019
Figure 20. Global Hepatic Encephalopathy Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Hepatic Encephalopathy Drug Revenue in 2019
Figure 22. Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Hepatic Encephalopathy Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Hepatic Encephalopathy Drug Sales Market Share by Type in 2019
Figure 25. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Hepatic Encephalopathy Drug Revenue Market Share by Type in 2019
Figure 27. Global Hepatic Encephalopathy Drug Market Share by Price Range (2015-2020)
Figure 28. Global Hepatic Encephalopathy Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Hepatic Encephalopathy Drug Sales Market Share by Application in 2019
Figure 30. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Hepatic Encephalopathy Drug Revenue Market Share by Application in 2019
Figure 32. North America Hepatic Encephalopathy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Hepatic Encephalopathy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Hepatic Encephalopathy Drug Sales Market Share by Country in 2019
Figure 35. North America Hepatic Encephalopathy Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Hepatic Encephalopathy Drug Market Share by Type in 2019
Figure 41. North America Hepatic Encephalopathy Drug Market Share by Application in 2019
Figure 42. Europe Hepatic Encephalopathy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Hepatic Encephalopathy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Hepatic Encephalopathy Drug Sales Market Share by Country in 2019
Figure 45. Europe Hepatic Encephalopathy Drug Revenue Market Share by Country in 2019
Figure 46. Germany Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Hepatic Encephalopathy Drug Market Share by Type in 2019
Figure 57. Europe Hepatic Encephalopathy Drug Market Share by Application in 2019
Figure 58. Asia Pacific Hepatic Encephalopathy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Hepatic Encephalopathy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Hepatic Encephalopathy Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Hepatic Encephalopathy Drug Revenue Market Share by Region in 2019
Figure 62. China Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Hepatic Encephalopathy Drug Market Share by Type in 2019
Figure 85. Asia Pacific Hepatic Encephalopathy Drug Market Share by Application in 2019
Figure 86. Latin America Hepatic Encephalopathy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Hepatic Encephalopathy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Hepatic Encephalopathy Drug Sales Market Share by Country in 2019
Figure 89. Latin America Hepatic Encephalopathy Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Hepatic Encephalopathy Drug Market Share by Type in 2019
Figure 97. Latin America Hepatic Encephalopathy Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Hepatic Encephalopathy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Hepatic Encephalopathy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Hepatic Encephalopathy Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Hepatic Encephalopathy Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Hepatic Encephalopathy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Hepatic Encephalopathy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Hepatic Encephalopathy Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Hepatic Encephalopathy Drug Market Share by Application in 2019
Figure 110. North America Hepatic Encephalopathy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Hepatic Encephalopathy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Hepatic Encephalopathy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Hepatic Encephalopathy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Hepatic Encephalopathy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Hepatic Encephalopathy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Hepatic Encephalopathy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Hepatic Encephalopathy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Hepatic Encephalopathy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Hepatic Encephalopathy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
肝性脳症（HE）治療薬の世界市場（～2026年） HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutic…- 顕性肝性脳症（OHE）の世界市場（～2026年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…
- 慢性外傷性脳症（CTE）の世界市場（～2026年） Chronic traumatic encephalopathy (CTE) is a kind of degenerative brain disease that is found in athletes, military veterans, and others with a history of repetitive brain trauma. Market Analysis and Insights: Global Chronic Traumatic Encephalopathy (CTE) Market The global Chronic Traumatic Encephalo…
- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…